Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000031.xml
Klin Monbl Augenheilkd 2016; 233(04): 488-489
DOI: 10.1055/s-0041-111805
DOI: 10.1055/s-0041-111805
Der interessante Fall
Recurrent Central Serous Chorioretinopathy Under Combined Vemurafenib and Cobimetinib Treatment
Rezidiv einer Chorioretinopathia centralis serosa unter Behandlung mit Vemurafenib und CobimetinibAuthors
Further Information
Publication History
Publication Date:
26 April 2016 (online)

Introduction
Mitogen-activated protein kinase (MAPK) inhibitor associated retinopathy (MAPK-retinopathy) resembling central serous chorioretinopathy (CSR) was described in few observational cohort-based studies [1], [2], [3] as well as in a case report [4]. Interestingly, the incidence of this complication seems to increase considerably under a combination of vemurafenib and cobimetinib as compared to vemurafenib monotherapy as was recently reported [2]. In this case symptoms of CSR started 3 days after introduction of vemurafenib and cobimetinib chemotherapy.
-
References
- 1 van Dijk EH, van Herpen CM et al. Serous retinopathy associated with mitogen-activated protein kinase inhibition (Binimetinib) for metastatic cutaneous and uveal melanoma. Ophthalmology 2015; 122: 1907-1916
- 2 Larkin J, Ascierto PA et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014; 371: 1867-1876
- 3 Urner-Bloch U, Urner M et al. Transient MEK inhibitor-associated retinopathy in metastatic melanoma. Ann Oncol 2014; 25: 1437-1441
- 4 McCannel TA, Chmielowski B et al. Bilateral subfoveal neurosensory retinal detachment associated with MEK inhibitor use for metastatic cancer. JAMA Ophthalmol 2014; 132: 1005-1009
- 5 Bouzas EA, Karadimas P, Pournaras CJ. Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol 2002; 47: 431-448
- 6 Imamura Y, Fujiwara T et al. Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina 2009; 29: 1469-1473
- 7 Gemenetzi M, De Salvo G, Lotery AJ. Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye 2010; 24: 1743-1756
- 8 Nicholson B, Noble J et al. Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol 2013; 58: 103-126
- 9 Yannuzzi LA. Type A behavior and central serous chorioretinopathy. Trans Am Ophthalmol Soc 1986; 84: 799-845
- 10 Kitzmann AS et al. The incidence of central serous chorioretinopathy in Olmsted County, Minessota, 1980–2002. Ophthalmology 2008; 115: 169-173